TCRCure Biopharma Corp.

TCRCure Biopharma aims to develop next generation cancer immunotherapies that control tumor progression, convert life-threatening cancers to manageable diseases, and eventually lead to cures. We are a leading international company focused on streamlined biotechnology development including high throughput antigen-specific TCR cloning, industry-scale virus production, T cell genetic engineering, and immune cell manufacturing. Founded by professors at Duke and USC, TCRCure Biopharma is a clinical stage biopharmaceutical company focused on the discovery and development of engineered autologous T cell products for cancer immunotherapy. Specifically, we identify novel chimeric antigen receptor (CAR) targets, screen antigen-specific T cell receptors (TCRs), modify CAR/TCR designs, and deploy CARs/TCRs to redirect patients’ T cells against solid tumors.